Enterome to Present New Clinical Data and Biomarker Findings for EO2463 at the 2024 American Society of Hematology (ASH) Annual Meeting
06. November 2024 06:00 ET
|
Enterome
Two poster presentations to feature novel data from the Phase 1/2 SIDNEY trial of EO2463 in indolent Non-Hodgkin Lymphoma (iNHL), highlighting initial data from Cohort 2 as monotherapy in a...
Enterome to Participate in the Jefferies Global Healthcare Conference
30. Mai 2024 06:00 ET
|
Enterome
PARIS, May 30, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024
24. Mai 2024 06:00 ET
|
Enterome
- Beneficial clinical responses observed with EO2463 monotherapy already at 6 weeks and complete response rate of 78% in patients treated with EO2463 upon addition of lenalidomide ± rituximab - ...
Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
25. April 2024 06:00 ET
|
Enterome
PARIS, April 25, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma
17. April 2024 06:00 ET
|
Enterome
EO2401, a pioneering OncoMimics™ peptide-based immunotherapy, has demonstrated rapid activation and significant expansion of existing effector memory T cells against tumor-associated driver antigens...
Enterome Announces Upcoming Presentation on OncoMimics™ Approach to Cancer Immunotherapy at the AACR Annual Meeting 2024
06. März 2024 06:42 ET
|
Enterome
PARIS, March 06, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
Enterome Appoints Industry Veteran Dr. Peter Hirth to its Board of Directors
18. Dezember 2023 06:00 ET
|
Enterome
PARIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on...
Enterome’s OncoMimics™ Immunotherapy EO2401 Significantly Improves Survival Rate in Recurrent Glioblastoma
20. November 2023 06:00 ET
|
Enterome
Positive data from the ROSALIE Phase 1/2 trial presented at 2023 SNO Annual Meeting Median survival of 14.5 months and 18-months survival rate of 43.1% in a 26-patient cohort where EO2401 was...
Enterome to Present Updated Data From Phase 1/2 ROSALIE Trial of its Peptide-Based Immunotherapy EO2401 in Recurrent Glioblastoma at SNO 2023
13. November 2023 06:00 ET
|
Enterome
PARIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
Enterome Presents Immune-Monitoring Data on EO2401 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
01. November 2023 07:00 ET
|
Enterome
Immune-monitoring data from the ongoing trials of EO2401 in adrenal tumors (SPENCER) and in recurrent glioblastoma (ROSALIE) High degree of homology with TAAs and robust immune responses validate the...